{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:39:04Z","timestamp":1776991144807,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tianjin Medical University General Hospital Excellent Youth Science Fund","award":["22ZYYYQ05"],"award-info":[{"award-number":["22ZYYYQ05"]}]},{"name":"Tianjin Natural Science Foundation Youth Project","award":["23JCQNJC01180"],"award-info":[{"award-number":["23JCQNJC01180"]}]},{"name":"Beijing-Tianjin-Hebei Special Project","award":["23JCZXJC00140"],"award-info":[{"award-number":["23JCZXJC00140"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82530032\uff0c82330031"],"award-info":[{"award-number":["82530032\uff0c82330031"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin","doi-asserted-by":"crossref","award":["25JCZDJC00390"],"award-info":[{"award-number":["25JCZDJC00390"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Tianjin Key Medical Discipline Construction Project","award":["NO. TJYXZDXK-3-004A"],"award-info":[{"award-number":["NO. TJYXZDXK-3-004A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-026-26994-1","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T03:33:31Z","timestamp":1773718411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world cost evaluation of conbercept vs. ranibizumab for retinal and choroidal vascular diseases from 2021 to 2024: evidence from societal and medical insurance perspectives"],"prefix":"10.1186","volume":"26","author":[{"given":"Yuanyuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinglin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanjing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiyun","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubens","family":"Belfort Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Antonio Brant","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"2","key":"26994_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Global health. 2014;2(2):e106\u2013116.","journal-title":"Lancet Global health"},{"issue":"4","key":"26994_CR2","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.survophthal.2022.01.009","volume":"67","author":"JHB Im","year":"2022","unstructured":"Im JHB, Jin YP, Chow R, Yan P. Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: A systematic review and meta-analysis. Surv Ophthalmol. 2022;67(4):1244\u201351.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"26994_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s42255-024-01190-w","volume":"7","author":"W Jia","year":"2025","unstructured":"Jia W, Chan JC, Wong TY, Fisher EB. Diabetes in China: epidemiology, pathophysiology and multi-omics. Nat metabolism. 2025;7(1):16\u201334.","journal-title":"Nat metabolism"},{"issue":"2","key":"26994_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313\u2013e319311.","journal-title":"Ophthalmology"},{"issue":"4","key":"26994_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ophtha.2012.09.033","volume":"120","author":"JQ Zhou","year":"2013","unstructured":"Zhou JQ, Xu L, Wang S, Wang YX, You QS, Tu Y, Yang H, Jonas JB. The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study. Ophthalmology. 2013;120(4):803\u20138.","journal-title":"Ophthalmology"},{"issue":"5","key":"26994_CR6","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/bjophthalmol-2021-320926","volume":"107","author":"Y Li","year":"2023","unstructured":"Li Y, Foo LL, Wong CW, Li J, Hoang QV, Schmetterer L, Ting DSW, Ang M. Pathologic myopia: advances in imaging and the potential role of artificial intelligence. Br J Ophthalmol. 2023;107(5):600\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"13","key":"26994_CR7","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193\u2013203.","journal-title":"N Engl J Med"},{"issue":"9","key":"26994_CR8","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","volume":"121","author":"X Li","year":"2014","unstructured":"Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, Zhang F, Zhang J, Tang L, Wu Q, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 2014;121(9):1740\u20137.","journal-title":"Ophthalmology"},{"issue":"11","key":"26994_CR9","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1080\/02713683.2020.1742357","volume":"45","author":"C Chen","year":"2020","unstructured":"Chen C, Yan M, Huang Z, Song YP. The Evaluation of a Two-Year Outcome of Intravitreal Conbercept versus Ranibizumab for Pathological Myopic Choroidal Neovascularization. Curr Eye Res. 2020;45(11):1415\u201321.","journal-title":"Curr Eye Res"},{"issue":"20","key":"26994_CR10","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1001\/jama.2017.4568","volume":"317","author":"IU Scott","year":"2017","unstructured":"Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. JAMA. 2017;317(20):2072\u201387.","journal-title":"JAMA"},{"issue":"1","key":"26994_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.oret.2018.08.002","volume":"3","author":"R Parikh","year":"2019","unstructured":"Parikh R, Pirakitikulr N, Chhablani J, Sakurada Y, Singh RP, Modi YS. A Multinational Comparison of Anti-Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific. Ophthalmol Retina. 2019;3(1):16\u201326.","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"26994_CR12","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/bjophthalmol-2021-319603","volume":"107","author":"G Jin","year":"2023","unstructured":"Jin G, Zou M, Liu C, Chen A, Sun Y, Young CA, Li Y, Zheng D, Congdon N, Han X. Burden of near vision loss in China: findings from the Global Burden of Disease Study 2019. Br J Ophthalmol. 2023;107(3):436\u201341.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"26994_CR13","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1080\/14737167.2022.2119130","volume":"22","author":"VG Svendsen","year":"2022","unstructured":"Svendsen VG, Lokkerbol J, Danner UN, Jansingh A, Evers SM, Wijnen BF. Design and testing of a health economic Markov model for treatment of anorexia nervosa. Expert Rev PharmacoEcon Outcomes Res. 2022;22(8):1243\u201351.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"issue":"12","key":"26994_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2165\/00019053-200220120-00006","volume":"20","author":"MJ Nuijten","year":"2002","unstructured":"Nuijten MJ, Rutten F. Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques. PharmacoEconomics. 2002;20(12):855\u201367.","journal-title":"PharmacoEconomics"},{"issue":"2","key":"26994_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-Related Macular Degeneration: A Review. JAMA. 2024;331(2):147\u201357.","journal-title":"JAMA"},{"issue":"2","key":"26994_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.17554\/j.issn.2409-5680.2016.02.35","volume":"2","author":"P Kolar","year":"2016","unstructured":"Kolar P. International Journal of Ophthalmic Research. Int J Ophthalmic Res. 2016;2(2):124\u20139.","journal-title":"Int J Ophthalmic Res"},{"issue":"11","key":"26994_CR17","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.ophtha.2017.04.028","volume":"124","author":"CMG Cheung","year":"2017","unstructured":"Cheung CMG, Arnold JJ, Holz FG, Park KH, Lai TYY, Larsen M, Mitchell P, Ohno-Matsui K, Chen SJ, Wolf S, et al. Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. Ophthalmology. 2017;124(11):1690\u2013711.","journal-title":"Ophthalmology"},{"key":"26994_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","volume":"197","author":"K Liu","year":"2019","unstructured":"Liu K, Song Y, Xu G, Ye J, Wu Z, Liu X, Dong X, Zhang M, Xing Y, Zhu S, et al. Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study. Am J Ophthalmol. 2019;197:156\u201367.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"26994_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40259-014-0106-1","volume":"28","author":"J Zhao","year":"2014","unstructured":"Zhao J, Li X, Tang S, Xu G, Xu X, Zhang F, Zhang M, Shamsazar J, Pilz S, Nieweg A. EXTEND II: an open-label phase III multicentre study to evaluate efficacy and safety of ranibizumab in Chinese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. BioDrugs: Clin immunotherapeutics biopharmaceuticals gene therapy. 2014;28(6):527\u201336.","journal-title":"BioDrugs: Clin immunotherapeutics biopharmaceuticals gene therapy"},{"key":"26994_CR20","unstructured":"Wei W. The Efficacy And Safety For Intravitreal Conbercept Injection In Patients With Macular Edema Secondary To Branch Retinal Vein Occlusion. Report presented at The 22nd European Society of Retina Specialists Congress. Hamburg: 2022."},{"issue":"1","key":"26994_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.oret.2019.08.001","volume":"4","author":"W Wei","year":"2020","unstructured":"Wei W, Weisberger A, Zhu L, Cheng Y, Liu C. Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study. Ophthalmol Retina. 2020;4(1):57\u201366.","journal-title":"Ophthalmol Retina"},{"key":"26994_CR22","unstructured":"Wei W. The Efficacy And Safety of Conbercept Ophthalmic Injection For Macular Edema Secondary to Central Retinal Vein Occlusion (CRAVE). Report presented at The 38th World Ophthalmology Congress 2022, 9-12 September, 2022, online."},{"key":"26994_CR23","unstructured":"Pharmaceuticals N. Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) (Camellia). In.; 2017-05-30. https:\/\/clinicaltrials.gov\/study\/NCT01976312?cond=Retinal%20Vein%20Occlusion&term=Camellia&rank=1#study-record-dates."},{"issue":"10","key":"26994_CR24","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/bjophthalmol-2020-318690","volume":"106","author":"K Liu","year":"2022","unstructured":"Liu K, Wang H, He W, Ye J, Song Y, Wang Y, Liu X, Wu Z, Chen S, Fan K, et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br J Ophthalmol. 2022;106(10):1436\u201343.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"26994_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00417-018-04213-x","volume":"257","author":"X Li","year":"2019","unstructured":"Li X, Dai H, Li X, Han M, Li J, Suhner A, Lin R, Wolf S. Efficacy and safety of ranibizumab 0.5\u00a0mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefe\u2019s archive Clin experimental Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2019;257(3):529\u201341.","journal-title":"Graefe\u2019s archive Clin experimental Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"},{"issue":"4","key":"26994_CR26","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1111\/aos.15810","volume":"102","author":"L Gao","year":"2024","unstructured":"Gao L, Song Y, Sun X, Zhang J, Liu Y, Chen Y, Wu Z, Jian Y, Liu X, Lv L, et al. Safety and efficacy of intravitreal injection of conbercept for the treatment of patients with choroidal neovascularization secondary to pathological myopia: Results from the SHINY study. Acta Ophthalmol. 2024;102(4):e577\u201386.","journal-title":"Acta Ophthalmol"},{"issue":"10","key":"26994_CR27","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1097\/IAE.0000000000002292","volume":"39","author":"Y Chen","year":"2019","unstructured":"Chen Y, Sharma T, Li X, Song Y, Chang Q, Lin R, Egger A, Foo A, Gekkieva M, Lai TYY. Ranibizumab versus verteporfin photodynamic therapy in asian patients with myopic choroidal neovascularization: Brilliance, a 12-Month, Randomized, Double-Masked Study. Retina (Philadelphia Pa). 2019;39(10):1985\u201394.","journal-title":"Retina (Philadelphia Pa)"},{"issue":"7","key":"26994_CR28","doi-asserted-by":"publisher","first-page":"e0201399","DOI":"10.1371\/journal.pone.0201399","volume":"13","author":"S Choi","year":"2018","unstructured":"Choi S, Park SM, Jee D. Utility values for age-related macular degeneration patients in Korea. PLoS ONE. 2018;13(7):e0201399.","journal-title":"PLoS ONE"},{"issue":"1","key":"26994_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12886-021-01997-1","volume":"21","author":"W Ni","year":"2021","unstructured":"Ni W, Liu J, Jiang Y, Wu J. Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective. BMC Ophthalmol. 2021;21(1):229.","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"26994_CR30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/j.1524-4733.2009.00527.x","volume":"12","author":"C Czoski-Murray","year":"2009","unstructured":"Czoski-Murray C, Carlton J, Brazier J, Young T, Papo NL, Kang HK. Valuing condition-specific health states using simulation contact lenses. Value health: J Int Soc Pharmacoeconomics Outcomes Res. 2009;12(5):793\u20139.","journal-title":"Value health: J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"26994_CR31","doi-asserted-by":"publisher","first-page":"101542","DOI":"10.1016\/j.vhri.2025.101542","volume":"53","author":"GS Paneerselvam","year":"2025","unstructured":"Paneerselvam GS, Wai NJ, Sheng LJ, Kenneth LKC. Cost-Effectiveness of Vascular Endothelial Growth Factor Inhibitors in the Management of Wet Age-Related Macular Degeneration: A Systematic Review. Value health Reg issues. 2025;53:101542.","journal-title":"Value health Reg issues"},{"issue":"1","key":"26994_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12962-025-00617-9","volume":"23","author":"C Xu","year":"2025","unstructured":"Xu C, Zhuang J, Shen J, Sun H, Cai J, Wei X. Cost-utility analysis of olaparib assisted targeted therapy for BRCA mutation HER2-negative early breast cancer in China and in the United States. Cost Eff resource allocation: C\/E. 2025;23(1):16.","journal-title":"Cost Eff resource allocation: C\/E"},{"key":"26994_CR33","doi-asserted-by":"publisher","first-page":"876386","DOI":"10.3389\/fphar.2022.876386","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, He X, Qi F, Liu J, Wu J. Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis. Front Pharmacol. 2022;13:876386.","journal-title":"Front Pharmacol"},{"issue":"7","key":"26994_CR34","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.18240\/ijo.2023.07.21","volume":"16","author":"Q Xing","year":"2023","unstructured":"Xing Q, Dai YN, Huang XB, Peng L. Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis. Int J Ophthalmol. 2023;16(7):1145\u201354.","journal-title":"Int J Ophthalmol"},{"issue":"7","key":"26994_CR35","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1136\/bjophthalmol-2020-318026","volume":"106","author":"Z Wu","year":"2022","unstructured":"Wu Z, Zhao J, Lam W, Yang M, Chen L, Huang X, Wei M, Yang H, Lv F, Zhang F, et al. Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial. Br J Ophthalmol. 2022;106(7):975\u20139.","journal-title":"Br J Ophthalmol"},{"key":"26994_CR36","doi-asserted-by":"publisher","first-page":"696201","DOI":"10.3389\/fphar.2021.696201","volume":"12","author":"P Zhou","year":"2021","unstructured":"Zhou P, Zheng S, Wang E, Men P, Zhai S. Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021;12:696201.","journal-title":"Front Pharmacol"},{"key":"26994_CR37","doi-asserted-by":"publisher","first-page":"750132","DOI":"10.3389\/fmed.2021.750132","volume":"8","author":"Z Cui","year":"2021","unstructured":"Cui Z, Zhou W, Chang Q, Zhang T, Wang H, Meng X, Liu Y, Yan H. Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model. Front Med. 2021;8:750132.","journal-title":"Front Med"},{"issue":"1","key":"26994_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12886-017-0554-8","volume":"17","author":"Y Xu","year":"2017","unstructured":"Xu Y, Rong A, Xu W, Niu Y, Wang Z. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study. BMC Ophthalmol. 2017;17(1):158.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"26994_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12886-019-1208-9","volume":"19","author":"V Daien","year":"2019","unstructured":"Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, Finger RP, Sakamoto T, Wong TY, Evuarherhe O, Carter G, et al. Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy - a systematic approach to identify and characterize data sources. BMC Ophthalmol. 2019;19(1):206.","journal-title":"BMC Ophthalmol"},{"issue":"9","key":"26994_CR40","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/j.ophtha.2014.03.029","volume":"121","author":"JS Chang","year":"2014","unstructured":"Chang JS, Smiddy WE. Cost evaluation of surgical and pharmaceutical options in treatment for vitreomacular adhesions and macular holes. Ophthalmology. 2014;121(9):1720\u20136.","journal-title":"Ophthalmology"},{"key":"26994_CR41","doi-asserted-by":"publisher","first-page":"1323090","DOI":"10.3389\/fpubh.2024.1323090","volume":"12","author":"S Lin","year":"2024","unstructured":"Lin S, Sun Q, Zhou H, Yin J, Zheng C. How medical insurance payment systems affect the physicians\u2019 provision behavior in China-based on experimental economics. Front public health. 2024;12:1323090.","journal-title":"Front public health"},{"issue":"1","key":"26994_CR42","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1186\/s12913-024-11950-9","volume":"24","author":"L Li","year":"2024","unstructured":"Li L, Yu Q. The impact of reform of medical insurance payment method on medical service pricing-based on empirical analysis of matched medical finance comprehensive data. BMC Health Serv Res. 2024;24(1):1479.","journal-title":"BMC Health Serv Res"},{"key":"26994_CR43","doi-asserted-by":"publisher","first-page":"100435","DOI":"10.1016\/j.lanwpc.2022.100435","volume":"23","author":"R Li","year":"2022","unstructured":"Li R, Yang Z, Zhang Y, Bai W, Du Y, Sun R, Tang J, Wang N, Liu H. Cost-effectiveness and cost-utility of traditional and telemedicine combined population-based age-related macular degeneration and diabetic retinopathy screening in rural and urban China. Lancet Reg health Western Pac. 2022;23:100435.","journal-title":"Lancet Reg health Western Pac"},{"issue":"9","key":"26994_CR44","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.ophtha.2018.02.038","volume":"125","author":"J Lin","year":"2018","unstructured":"Lin J, Chang JS, Yannuzzi NA, Smiddy WE. Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy. Ophthalmology. 2018;125(9):1393\u2013400.","journal-title":"Ophthalmology"},{"issue":"6","key":"26994_CR45","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamaophthalmol.2023.1463","volume":"141","author":"SM Kymes","year":"2023","unstructured":"Kymes SM, Oden NL, VanVeldhuisen PC, Scott IU, Ip MS, Blodi BA, King J. Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial. JAMA Ophthalmol. 2023;141(6):554\u201361.","journal-title":"JAMA Ophthalmol"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-026-26994-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-26994-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-26994-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:02:53Z","timestamp":1776988973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-026-26994-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["26994"],"URL":"https:\/\/doi.org\/10.1186\/s12889-026-26994-1","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been in line with the principles of the Declaration of Helsinki and approved by the Ethics Committee of Tianjin Medical University General Hospital, China with No. IRB2020-YX-160-01. Since there were no identical information about the patients were reported, the need for consent to participate was waived by an Institutional Review Board (IRB) as Ethics Committee of Tianjin Medical University General Hospital, China with No. IRB2020-YX-160-01.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1339"}}